Navigation Links
Other patients bear the real cost of Herceptin

The real cost of Herceptin is borne by other patients whose treatment has to be dropped to balance the books, say doctors in this week’s BMJ.

New guidance from the National Institute for health and Clinical Excellence (NICE) recommends trastuzumab (Herceptin) in early breast cancer, but it provides no extra funding and does not suggest what cuts should be made to release this extra money. This leaves medical staff with difficult decisions to make.

Doctors at the Norfolk and Norwich University Hospital NHS Trust and the University of East Anglia calculated that they will have to find £1.9m each year to make Herceptin available to the patients who may be eligible. This becomes £2.3m if the costs of testing and monitoring patients are added.

But the real cost lies in the services that will be cut to provide this money, they write.

To illustrate this, they audited drug costs in their hospital’s cancer centre and estimated how they could save £1.9m by cutting chemotherapy and palliative care treatments.

The sum of £1.9m would enable us to treat 75 patients with Herceptin, but at four times the cost of the adjuvant treatments, they say. These treatments have been proved to be clinically effective and their estimated cost effectiveness is far greater than that currently expected for Herceptin.

So they could fund Herceptin if they did not treat 355 patients receiving adjuvant treatment (16 of whom would be cured) or 208 patients receiving palliative chemotherapy, and if they found £500,000 from another source.

“These untreated patients will be people we know,?say the authors. “We will be the ones to tell them they are not getting treatment that has been proved to be effective and which costs relatively little, because it is not the treatment of the moment.?

These results are obviously not definitive, but illustrate the fundamental challenge facing the NHS ?the tension between national priority setti ng and local implementation, they add.

This situation highlights our central argument, that as NICE guidance provides no extra funding or any suggestion of which services to cut, medical professionals ultimately have to make these decisions.

Political pressure, patient advocacy and media hyperbole should not be the determinant of who is treated and with what, they argue. In NICE we have an established system, but it is currently creating more problems than solutions.

They believe that NICE should be given responsibility to decide what should be cut to fund newly recommended technologies or the ability to allocate extra funds for implementation, or both.
'"/>

Source:BMJ-British Medical Journal


Related biology news :

1. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
2. Otherworldly bacteria discovered two miles down
3. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
4. Potential Cure for Lymphoma in HIV patients
5. Ophthalmologists implant five patients with artificial silicon retina microchip
6. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
7. Measuring hormone cuts antibiotic use in half in pneumonia patients
8. Doctors closer to using gene analysis to help trauma patients
9. Research shows smoking adds a decade to reproductive age of IVF patients
10. Columbia study shows widely used artery clearing device does not help patients during heart attack
11. Identification of specific genes predicts which patients will respond to Hepatitis C treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... , ... August 16, 2017 , ... While art and ... much more closely connected than one might think. A Mesh Is Also a ... at the University City Science Center’s Esther Klein Gallery (EKG) on August 17 and ...
(Date:8/16/2017)... BOSTON and OXFORD, England , ... -based consortium for biotech executive search and leadership development, ... and Healthcare sectors, have created an exclusive alliance that enables ... "For our clients here ... collaboration provides unparalleled access to a diverse population of leadership ...
(Date:8/15/2017)... Pittsburgh, PA (PRWEB) , ... August 15, 2017 ... ... JASIS, one of the largest Asian exhibitions for analytical and scientific instruments. This ... Pittsburgh), will be “New Approaches in Mass Spectrometry for Bioanalytical Applications.” This dynamic ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... is threatened by various biotic and abiotic factors. During this educational webinar, participants ... of coffee, as well as gain a better understanding of how genomics is ...
Breaking Biology Technology: